We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 2% above its sector, the market expects faster growth.
Shenzhen Weiguang Biological Products Co., Ltd. is a Chinese enterprise primarily dedicated to the entire lifecycle of blood products, encompassing their research, development, manufacturing, and distribution within the domestic market. Its comprehensive portfolio features a range of crucial blood-derived therapies, including human albumin, various intravenous immunoglobulin preparations (such as pH4 and its freeze-dried counterpart), general human immunoglobulin, and specific immunoglobulins targeting conditions like hepatitis B, rabies, and tetanus. Additionally, it provides histamine human immunoglobulin and human fibrinogen. These offerings collectively represent nine distinct product types, available in twenty-one different specifications. Established in 1985, the firm maintains its headquarters in Shenzhen, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 002880.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
